nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—XDH—Carboplatin—urinary bladder cancer	0.1	0.217	CbGbCtD
Carvedilol—XDH—Cisplatin—urinary bladder cancer	0.0855	0.185	CbGbCtD
Carvedilol—XDH—Doxorubicin—urinary bladder cancer	0.0573	0.124	CbGbCtD
Carvedilol—ABCB1—Mitomycin—urinary bladder cancer	0.0466	0.101	CbGbCtD
Carvedilol—PTGS1—Etoposide—urinary bladder cancer	0.0245	0.0531	CbGbCtD
Carvedilol—CYP3A4—Thiotepa—urinary bladder cancer	0.0212	0.0458	CbGbCtD
Carvedilol—CYP2E1—Etoposide—urinary bladder cancer	0.0189	0.041	CbGbCtD
Carvedilol—ADRA1B—vas deferens—urinary bladder cancer	0.0142	0.0916	CbGeAlD
Carvedilol—ABCB1—Gemcitabine—urinary bladder cancer	0.0134	0.0291	CbGbCtD
Carvedilol—CYP1A2—Fluorouracil—urinary bladder cancer	0.0131	0.0284	CbGbCtD
Carvedilol—CYP2C9—Fluorouracil—urinary bladder cancer	0.0118	0.0256	CbGbCtD
Carvedilol—CYP1A2—Etoposide—urinary bladder cancer	0.0109	0.0237	CbGbCtD
Carvedilol—CYP2C9—Cisplatin—urinary bladder cancer	0.01	0.0218	CbGbCtD
Carvedilol—ABCB1—Cisplatin—urinary bladder cancer	0.00974	0.0211	CbGbCtD
Carvedilol—SELE—umbilical vein—urinary bladder cancer	0.00964	0.0624	CbGeAlD
Carvedilol—ABCB1—Etoposide—urinary bladder cancer	0.00957	0.0207	CbGbCtD
Carvedilol—VCAM1—umbilical vein—urinary bladder cancer	0.00887	0.0574	CbGeAlD
Carvedilol—ABCB1—Doxorubicin—urinary bladder cancer	0.00653	0.0142	CbGbCtD
Carvedilol—ABCB1—Methotrexate—urinary bladder cancer	0.00632	0.0137	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—urinary bladder cancer	0.00615	0.0133	CbGbCtD
Carvedilol—CYP3A4—Etoposide—urinary bladder cancer	0.00573	0.0124	CbGbCtD
Carvedilol—CYP3A4—Doxorubicin—urinary bladder cancer	0.00391	0.00848	CbGbCtD
Carvedilol—NPPB—smooth muscle tissue—urinary bladder cancer	0.00293	0.0189	CbGeAlD
Carvedilol—SELE—prostate gland—urinary bladder cancer	0.00279	0.0181	CbGeAlD
Carvedilol—VCAM1—prostate gland—urinary bladder cancer	0.00257	0.0166	CbGeAlD
Carvedilol—HIF1A—prostate gland—urinary bladder cancer	0.00247	0.016	CbGeAlD
Carvedilol—GJA1—prostate gland—urinary bladder cancer	0.0024	0.0155	CbGeAlD
Carvedilol—SELE—seminal vesicle—urinary bladder cancer	0.00236	0.0153	CbGeAlD
Carvedilol—ADRB3—prostate gland—urinary bladder cancer	0.0022	0.0142	CbGeAlD
Carvedilol—VCAM1—seminal vesicle—urinary bladder cancer	0.00217	0.0141	CbGeAlD
Carvedilol—HIF1A—seminal vesicle—urinary bladder cancer	0.00209	0.0135	CbGeAlD
Carvedilol—NDUFC2—prostate gland—urinary bladder cancer	0.00209	0.0135	CbGeAlD
Carvedilol—SELE—epithelium—urinary bladder cancer	0.00205	0.0133	CbGeAlD
Carvedilol—GJA1—seminal vesicle—urinary bladder cancer	0.00203	0.0131	CbGeAlD
Carvedilol—SELE—smooth muscle tissue—urinary bladder cancer	0.00198	0.0128	CbGeAlD
Carvedilol—SELE—renal system—urinary bladder cancer	0.0019	0.0123	CbGeAlD
Carvedilol—VEGFA—prostate gland—urinary bladder cancer	0.00189	0.0122	CbGeAlD
Carvedilol—VCAM1—epithelium—urinary bladder cancer	0.00189	0.0122	CbGeAlD
Carvedilol—SELE—urethra—urinary bladder cancer	0.00187	0.0121	CbGeAlD
Carvedilol—VCAM1—smooth muscle tissue—urinary bladder cancer	0.00182	0.0118	CbGeAlD
Carvedilol—HIF1A—epithelium—urinary bladder cancer	0.00182	0.0117	CbGeAlD
Carvedilol—NDUFC2—seminal vesicle—urinary bladder cancer	0.00176	0.0114	CbGeAlD
Carvedilol—GJA1—epithelium—urinary bladder cancer	0.00176	0.0114	CbGeAlD
Carvedilol—VCAM1—renal system—urinary bladder cancer	0.00175	0.0113	CbGeAlD
Carvedilol—HIF1A—smooth muscle tissue—urinary bladder cancer	0.00175	0.0113	CbGeAlD
Carvedilol—VCAM1—urethra—urinary bladder cancer	0.00172	0.0111	CbGeAlD
Carvedilol—GJA1—smooth muscle tissue—urinary bladder cancer	0.0017	0.011	CbGeAlD
Carvedilol—XDH—prostate gland—urinary bladder cancer	0.00168	0.0109	CbGeAlD
Carvedilol—HIF1A—renal system—urinary bladder cancer	0.00168	0.0109	CbGeAlD
Carvedilol—HIF1A—urethra—urinary bladder cancer	0.00165	0.0107	CbGeAlD
Carvedilol—CYP1A2—urine—urinary bladder cancer	0.00164	0.0106	CbGeAlD
Carvedilol—GJA1—renal system—urinary bladder cancer	0.00163	0.0106	CbGeAlD
Carvedilol—GJA1—urethra—urinary bladder cancer	0.0016	0.0104	CbGeAlD
Carvedilol—CYP2C9—urine—urinary bladder cancer	0.00155	0.01	CbGeAlD
Carvedilol—NDUFC2—epithelium—urinary bladder cancer	0.00153	0.00992	CbGeAlD
Carvedilol—SELE—female reproductive system—urinary bladder cancer	0.00152	0.00986	CbGeAlD
Carvedilol—CYP2E1—urine—urinary bladder cancer	0.00147	0.00952	CbGeAlD
Carvedilol—NDUFC2—renal system—urinary bladder cancer	0.00142	0.0092	CbGeAlD
Carvedilol—VCAM1—female reproductive system—urinary bladder cancer	0.0014	0.00907	CbGeAlD
Carvedilol—NDUFC2—urethra—urinary bladder cancer	0.0014	0.00904	CbGeAlD
Carvedilol—SELE—vagina—urinary bladder cancer	0.00138	0.00892	CbGeAlD
Carvedilol—HIF1A—female reproductive system—urinary bladder cancer	0.00135	0.00873	CbGeAlD
Carvedilol—VEGFA—smooth muscle tissue—urinary bladder cancer	0.00134	0.00867	CbGeAlD
Carvedilol—GJA1—female reproductive system—urinary bladder cancer	0.00131	0.00846	CbGeAlD
Carvedilol—VCAM1—vagina—urinary bladder cancer	0.00127	0.0082	CbGeAlD
Carvedilol—VEGFA—urethra—urinary bladder cancer	0.00127	0.0082	CbGeAlD
Carvedilol—ADRA1D—prostate gland—urinary bladder cancer	0.00124	0.008	CbGeAlD
Carvedilol—HIF1A—vagina—urinary bladder cancer	0.00122	0.00789	CbGeAlD
Carvedilol—ADRB3—female reproductive system—urinary bladder cancer	0.0012	0.00776	CbGeAlD
Carvedilol—CYP3A4—urine—urinary bladder cancer	0.00118	0.00766	CbGeAlD
Carvedilol—GJA1—vagina—urinary bladder cancer	0.00118	0.00766	CbGeAlD
Carvedilol—CYP2D6—urine—urinary bladder cancer	0.00117	0.00754	CbGeAlD
Carvedilol—XDH—renal system—urinary bladder cancer	0.00115	0.00743	CbGeAlD
Carvedilol—NDUFC2—female reproductive system—urinary bladder cancer	0.00114	0.00737	CbGeAlD
Carvedilol—NDUFC2—vagina—urinary bladder cancer	0.00103	0.00666	CbGeAlD
Carvedilol—VEGFA—vagina—urinary bladder cancer	0.000934	0.00605	CbGeAlD
Carvedilol—XDH—female reproductive system—urinary bladder cancer	0.00092	0.00595	CbGeAlD
Carvedilol—ADRA1D—epithelium—urinary bladder cancer	0.000909	0.00588	CbGeAlD
Carvedilol—ADRB1—prostate gland—urinary bladder cancer	0.000898	0.00581	CbGeAlD
Carvedilol—SELE—lymph node—urinary bladder cancer	0.000892	0.00577	CbGeAlD
Carvedilol—ADRA1B—renal system—urinary bladder cancer	0.000862	0.00557	CbGeAlD
Carvedilol—XDH—vagina—urinary bladder cancer	0.000832	0.00538	CbGeAlD
Carvedilol—ADRA1D—urethra—urinary bladder cancer	0.000828	0.00536	CbGeAlD
Carvedilol—VCAM1—lymph node—urinary bladder cancer	0.00082	0.00531	CbGeAlD
Carvedilol—HIF1A—lymph node—urinary bladder cancer	0.000789	0.0051	CbGeAlD
Carvedilol—GJA1—lymph node—urinary bladder cancer	0.000765	0.00495	CbGeAlD
Carvedilol—ADRA1A—prostate gland—urinary bladder cancer	0.00071	0.00459	CbGeAlD
Carvedilol—KCNH2—prostate gland—urinary bladder cancer	0.000686	0.00444	CbGeAlD
Carvedilol—ADRA2C—prostate gland—urinary bladder cancer	0.000677	0.00438	CbGeAlD
Carvedilol—ADRA1D—female reproductive system—urinary bladder cancer	0.000675	0.00437	CbGeAlD
Carvedilol—NDUFC2—lymph node—urinary bladder cancer	0.000666	0.00431	CbGeAlD
Carvedilol—VEGFA—lymph node—urinary bladder cancer	0.000604	0.00391	CbGeAlD
Carvedilol—KCNH2—seminal vesicle—urinary bladder cancer	0.00058	0.00375	CbGeAlD
Carvedilol—ADRA2C—seminal vesicle—urinary bladder cancer	0.000572	0.0037	CbGeAlD
Carvedilol—ADRA2A—prostate gland—urinary bladder cancer	0.00054	0.00349	CbGeAlD
Carvedilol—CYP2E1—prostate gland—urinary bladder cancer	0.000528	0.00342	CbGeAlD
Carvedilol—ADRA1A—epithelium—urinary bladder cancer	0.000522	0.00338	CbGeAlD
Carvedilol—PTGS1—prostate gland—urinary bladder cancer	0.000509	0.00329	CbGeAlD
Carvedilol—ADRB1—female reproductive system—urinary bladder cancer	0.00049	0.00317	CbGeAlD
Carvedilol—ADRA1A—renal system—urinary bladder cancer	0.000484	0.00313	CbGeAlD
Carvedilol—KCNH2—renal system—urinary bladder cancer	0.000468	0.00302	CbGeAlD
Carvedilol—ADRA2C—renal system—urinary bladder cancer	0.000461	0.00298	CbGeAlD
Carvedilol—KCNH2—urethra—urinary bladder cancer	0.000459	0.00297	CbGeAlD
Carvedilol—ADRA2A—seminal vesicle—urinary bladder cancer	0.000457	0.00295	CbGeAlD
Carvedilol—ADRA2C—urethra—urinary bladder cancer	0.000453	0.00293	CbGeAlD
Carvedilol—CYP2E1—seminal vesicle—urinary bladder cancer	0.000447	0.00289	CbGeAlD
Carvedilol—PTGS1—seminal vesicle—urinary bladder cancer	0.00043	0.00278	CbGeAlD
Carvedilol—CYP1A1—epithelium—urinary bladder cancer	0.000426	0.00275	CbGeAlD
Carvedilol—CYP1A2—renal system—urinary bladder cancer	0.0004	0.00259	CbGeAlD
Carvedilol—CYP1A1—renal system—urinary bladder cancer	0.000395	0.00255	CbGeAlD
Carvedilol—CYP1A1—urethra—urinary bladder cancer	0.000388	0.00251	CbGeAlD
Carvedilol—KCNH2—female reproductive system—urinary bladder cancer	0.000374	0.00242	CbGeAlD
Carvedilol—PTGS1—epithelium—urinary bladder cancer	0.000374	0.00242	CbGeAlD
Carvedilol—ADRA2A—urethra—urinary bladder cancer	0.000362	0.00234	CbGeAlD
Carvedilol—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00036	0.00233	CbGeAlD
Carvedilol—CYP2E1—renal system—urinary bladder cancer	0.00036	0.00233	CbGeAlD
Carvedilol—CYP2E1—urethra—urinary bladder cancer	0.000354	0.00229	CbGeAlD
Carvedilol—PTGS1—renal system—urinary bladder cancer	0.000347	0.00224	CbGeAlD
Carvedilol—KCNH2—vagina—urinary bladder cancer	0.000339	0.00219	CbGeAlD
Carvedilol—ADRA2C—vagina—urinary bladder cancer	0.000334	0.00216	CbGeAlD
Carvedilol—CYP1A1—female reproductive system—urinary bladder cancer	0.000316	0.00205	CbGeAlD
Carvedilol—CYP2C9—female reproductive system—urinary bladder cancer	0.000304	0.00197	CbGeAlD
Carvedilol—ABCB1—prostate gland—urinary bladder cancer	0.000301	0.00195	CbGeAlD
Carvedilol—ADRA2A—female reproductive system—urinary bladder cancer	0.000295	0.00191	CbGeAlD
Carvedilol—CYP3A4—renal system—urinary bladder cancer	0.00029	0.00187	CbGeAlD
Carvedilol—CYP2E1—female reproductive system—urinary bladder cancer	0.000288	0.00187	CbGeAlD
Carvedilol—CYP1A1—vagina—urinary bladder cancer	0.000286	0.00185	CbGeAlD
Carvedilol—CYP2D6—renal system—urinary bladder cancer	0.000285	0.00184	CbGeAlD
Carvedilol—PTGS1—female reproductive system—urinary bladder cancer	0.000278	0.0018	CbGeAlD
Carvedilol—ADRA2A—vagina—urinary bladder cancer	0.000267	0.00172	CbGeAlD
Carvedilol—ABCB1—seminal vesicle—urinary bladder cancer	0.000254	0.00165	CbGeAlD
Carvedilol—PTGS1—vagina—urinary bladder cancer	0.000251	0.00163	CbGeAlD
Carvedilol—CYP3A4—female reproductive system—urinary bladder cancer	0.000232	0.0015	CbGeAlD
Carvedilol—CYP2D6—female reproductive system—urinary bladder cancer	0.000228	0.00148	CbGeAlD
Carvedilol—ABCB1—epithelium—urinary bladder cancer	0.000221	0.00143	CbGeAlD
Carvedilol—KCNH2—lymph node—urinary bladder cancer	0.000219	0.00142	CbGeAlD
Carvedilol—ADRA2C—lymph node—urinary bladder cancer	0.000216	0.0014	CbGeAlD
Carvedilol—ABCB1—renal system—urinary bladder cancer	0.000205	0.00133	CbGeAlD
Carvedilol—ABCB1—urethra—urinary bladder cancer	0.000201	0.0013	CbGeAlD
Carvedilol—CYP1A1—lymph node—urinary bladder cancer	0.000185	0.0012	CbGeAlD
Carvedilol—ADRA2A—lymph node—urinary bladder cancer	0.000172	0.00112	CbGeAlD
Carvedilol—ABCB1—female reproductive system—urinary bladder cancer	0.000164	0.00106	CbGeAlD
Carvedilol—PTGS1—lymph node—urinary bladder cancer	0.000163	0.00105	CbGeAlD
Carvedilol—ABCB1—vagina—urinary bladder cancer	0.000149	0.000961	CbGeAlD
Carvedilol—Pneumonia—Doxorubicin—urinary bladder cancer	0.000112	0.000575	CcSEcCtD
Carvedilol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000112	0.000574	CcSEcCtD
Carvedilol—Pruritus—Fluorouracil—urinary bladder cancer	0.000112	0.000572	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—urinary bladder cancer	0.000111	0.000571	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000111	0.000566	CcSEcCtD
Carvedilol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00011	0.000565	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—urinary bladder cancer	0.00011	0.000564	CcSEcCtD
Carvedilol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00011	0.000563	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—urinary bladder cancer	0.00011	0.000561	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000109	0.00056	CcSEcCtD
Carvedilol—Urticaria—Etoposide—urinary bladder cancer	0.000109	0.000558	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—urinary bladder cancer	0.000109	0.000557	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—urinary bladder cancer	0.000109	0.000556	CcSEcCtD
Carvedilol—Abdominal pain—Etoposide—urinary bladder cancer	0.000108	0.000555	CcSEcCtD
Carvedilol—Body temperature increased—Etoposide—urinary bladder cancer	0.000108	0.000555	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000108	0.000555	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—urinary bladder cancer	0.000108	0.000554	CcSEcCtD
Carvedilol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000108	0.000553	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—urinary bladder cancer	0.000108	0.000552	CcSEcCtD
Carvedilol—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000108	0.000551	CcSEcCtD
Carvedilol—Asthenia—Cisplatin—urinary bladder cancer	0.000107	0.00055	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—urinary bladder cancer	0.000107	0.00055	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000107	0.000547	CcSEcCtD
Carvedilol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000107	0.000546	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—urinary bladder cancer	0.000106	0.000545	CcSEcCtD
Carvedilol—Urethral disorder—Epirubicin—urinary bladder cancer	0.000106	0.000543	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—urinary bladder cancer	0.000105	0.000537	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—urinary bladder cancer	0.000105	0.000536	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000104	0.000535	CcSEcCtD
Carvedilol—Dizziness—Fluorouracil—urinary bladder cancer	0.000104	0.000535	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—urinary bladder cancer	0.000104	0.000534	CcSEcCtD
Carvedilol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000104	0.000534	CcSEcCtD
Carvedilol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000102	0.000525	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000102	0.000524	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—urinary bladder cancer	0.000102	0.000523	CcSEcCtD
Carvedilol—Vomiting—Gemcitabine—urinary bladder cancer	0.000102	0.000523	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—urinary bladder cancer	0.000102	0.000522	CcSEcCtD
Carvedilol—Rash—Gemcitabine—urinary bladder cancer	0.000101	0.000519	CcSEcCtD
Carvedilol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000101	0.000518	CcSEcCtD
Carvedilol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000101	0.000517	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—urinary bladder cancer	0.000101	0.000517	CcSEcCtD
Carvedilol—Malnutrition—Methotrexate—urinary bladder cancer	0.000101	0.000515	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000101	0.000515	CcSEcCtD
Carvedilol—Headache—Gemcitabine—urinary bladder cancer	0.000101	0.000515	CcSEcCtD
Carvedilol—Vomiting—Fluorouracil—urinary bladder cancer	0.0001	0.000514	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—urinary bladder cancer	0.0001	0.000514	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—urinary bladder cancer	0.0001	0.000513	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—urinary bladder cancer	9.97e-05	0.00051	CcSEcCtD
Carvedilol—Rash—Fluorouracil—urinary bladder cancer	9.96e-05	0.00051	CcSEcCtD
Carvedilol—Dermatitis—Fluorouracil—urinary bladder cancer	9.95e-05	0.000509	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—urinary bladder cancer	9.94e-05	0.000509	CcSEcCtD
Carvedilol—Headache—Fluorouracil—urinary bladder cancer	9.9e-05	0.000507	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—urinary bladder cancer	9.89e-05	0.000506	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—urinary bladder cancer	9.87e-05	0.000505	CcSEcCtD
Carvedilol—Asthenia—Etoposide—urinary bladder cancer	9.85e-05	0.000504	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—urinary bladder cancer	9.82e-05	0.000503	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—urinary bladder cancer	9.82e-05	0.000503	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—urinary bladder cancer	9.78e-05	0.000501	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—urinary bladder cancer	9.76e-05	0.000499	CcSEcCtD
Carvedilol—Back pain—Methotrexate—urinary bladder cancer	9.74e-05	0.000499	CcSEcCtD
Carvedilol—Pruritus—Etoposide—urinary bladder cancer	9.71e-05	0.000497	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—urinary bladder cancer	9.65e-05	0.000494	CcSEcCtD
Carvedilol—ABCB1—lymph node—urinary bladder cancer	9.61e-05	0.000622	CbGeAlD
Carvedilol—Alopecia—Epirubicin—urinary bladder cancer	9.57e-05	0.00049	CcSEcCtD
Carvedilol—Nausea—Gemcitabine—urinary bladder cancer	9.55e-05	0.000489	CcSEcCtD
Carvedilol—Vomiting—Cisplatin—urinary bladder cancer	9.52e-05	0.000487	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—urinary bladder cancer	9.49e-05	0.000486	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—urinary bladder cancer	9.47e-05	0.000485	CcSEcCtD
Carvedilol—Rash—Cisplatin—urinary bladder cancer	9.44e-05	0.000483	CcSEcCtD
Carvedilol—Dermatitis—Cisplatin—urinary bladder cancer	9.44e-05	0.000483	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—urinary bladder cancer	9.42e-05	0.000482	CcSEcCtD
Carvedilol—Diarrhoea—Etoposide—urinary bladder cancer	9.39e-05	0.000481	CcSEcCtD
Carvedilol—Nausea—Fluorouracil—urinary bladder cancer	9.39e-05	0.00048	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—urinary bladder cancer	9.34e-05	0.000478	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—urinary bladder cancer	9.34e-05	0.000478	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—urinary bladder cancer	9.31e-05	0.000476	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—urinary bladder cancer	9.29e-05	0.000475	CcSEcCtD
Carvedilol—Tension—Epirubicin—urinary bladder cancer	9.25e-05	0.000473	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—urinary bladder cancer	9.15e-05	0.000469	CcSEcCtD
Carvedilol—Back pain—Epirubicin—urinary bladder cancer	9.12e-05	0.000467	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—urinary bladder cancer	9.09e-05	0.000465	CcSEcCtD
Carvedilol—Malaise—Methotrexate—urinary bladder cancer	9.08e-05	0.000465	CcSEcCtD
Carvedilol—Dizziness—Etoposide—urinary bladder cancer	9.07e-05	0.000464	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—urinary bladder cancer	9.06e-05	0.000464	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—urinary bladder cancer	9.05e-05	0.000463	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—urinary bladder cancer	9.05e-05	0.000463	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	9.03e-05	0.000462	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—urinary bladder cancer	9.01e-05	0.000461	CcSEcCtD
Carvedilol—Nausea—Cisplatin—urinary bladder cancer	8.9e-05	0.000455	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—urinary bladder cancer	8.88e-05	0.000455	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—urinary bladder cancer	8.85e-05	0.000453	CcSEcCtD
Carvedilol—Cough—Methotrexate—urinary bladder cancer	8.79e-05	0.00045	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.74e-05	0.000448	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—urinary bladder cancer	8.73e-05	0.000447	CcSEcCtD
Carvedilol—Vomiting—Etoposide—urinary bladder cancer	8.72e-05	0.000447	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—urinary bladder cancer	8.72e-05	0.000446	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—urinary bladder cancer	8.71e-05	0.000446	CcSEcCtD
Carvedilol—Rash—Etoposide—urinary bladder cancer	8.65e-05	0.000443	CcSEcCtD
Carvedilol—Dermatitis—Etoposide—urinary bladder cancer	8.64e-05	0.000442	CcSEcCtD
Carvedilol—Headache—Etoposide—urinary bladder cancer	8.6e-05	0.00044	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—urinary bladder cancer	8.59e-05	0.00044	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—urinary bladder cancer	8.57e-05	0.000439	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—urinary bladder cancer	8.57e-05	0.000439	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—urinary bladder cancer	8.57e-05	0.000439	CcSEcCtD
Carvedilol—Tension—Doxorubicin—urinary bladder cancer	8.56e-05	0.000438	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.52e-05	0.000436	CcSEcCtD
Carvedilol—Malaise—Epirubicin—urinary bladder cancer	8.5e-05	0.000435	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—urinary bladder cancer	8.47e-05	0.000434	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—urinary bladder cancer	8.47e-05	0.000434	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—urinary bladder cancer	8.47e-05	0.000433	CcSEcCtD
Carvedilol—Syncope—Epirubicin—urinary bladder cancer	8.45e-05	0.000433	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—urinary bladder cancer	8.44e-05	0.000432	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—urinary bladder cancer	8.44e-05	0.000432	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—urinary bladder cancer	8.38e-05	0.000429	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—urinary bladder cancer	8.33e-05	0.000426	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—urinary bladder cancer	8.29e-05	0.000424	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—urinary bladder cancer	8.28e-05	0.000424	CcSEcCtD
Carvedilol—Cough—Epirubicin—urinary bladder cancer	8.22e-05	0.000421	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—urinary bladder cancer	8.22e-05	0.000421	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—urinary bladder cancer	8.22e-05	0.000421	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—urinary bladder cancer	8.17e-05	0.000418	CcSEcCtD
Carvedilol—Infection—Methotrexate—urinary bladder cancer	8.17e-05	0.000418	CcSEcCtD
Carvedilol—Nausea—Etoposide—urinary bladder cancer	8.15e-05	0.000417	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—urinary bladder cancer	8.14e-05	0.000416	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—urinary bladder cancer	8.09e-05	0.000414	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—urinary bladder cancer	8.06e-05	0.000413	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.05e-05	0.000412	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—urinary bladder cancer	8.02e-05	0.000411	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—urinary bladder cancer	8.02e-05	0.000411	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—urinary bladder cancer	8.02e-05	0.000411	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—urinary bladder cancer	7.98e-05	0.000409	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.97e-05	0.000408	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.95e-05	0.000407	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—urinary bladder cancer	7.93e-05	0.000406	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—urinary bladder cancer	7.86e-05	0.000403	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—urinary bladder cancer	7.85e-05	0.000402	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—urinary bladder cancer	7.83e-05	0.000401	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—urinary bladder cancer	7.83e-05	0.000401	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—urinary bladder cancer	7.82e-05	0.0004	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—urinary bladder cancer	7.81e-05	0.0004	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—urinary bladder cancer	7.76e-05	0.000397	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—urinary bladder cancer	7.71e-05	0.000394	CcSEcCtD
Carvedilol—Oedema—Epirubicin—urinary bladder cancer	7.69e-05	0.000394	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.69e-05	0.000394	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—urinary bladder cancer	7.68e-05	0.000393	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.66e-05	0.000392	CcSEcCtD
Carvedilol—Infection—Epirubicin—urinary bladder cancer	7.64e-05	0.000391	CcSEcCtD
Carvedilol—Cough—Doxorubicin—urinary bladder cancer	7.61e-05	0.00039	CcSEcCtD
Carvedilol—Shock—Epirubicin—urinary bladder cancer	7.57e-05	0.000387	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—urinary bladder cancer	7.56e-05	0.000387	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.53e-05	0.000385	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—urinary bladder cancer	7.53e-05	0.000385	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—urinary bladder cancer	7.51e-05	0.000384	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.49e-05	0.000383	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—urinary bladder cancer	7.47e-05	0.000382	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.44e-05	0.000381	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—urinary bladder cancer	7.43e-05	0.000381	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—urinary bladder cancer	7.42e-05	0.00038	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—urinary bladder cancer	7.42e-05	0.00038	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—urinary bladder cancer	7.42e-05	0.00038	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—urinary bladder cancer	7.38e-05	0.000378	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.37e-05	0.000377	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—urinary bladder cancer	7.34e-05	0.000375	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—urinary bladder cancer	7.33e-05	0.000375	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—urinary bladder cancer	7.33e-05	0.000375	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—urinary bladder cancer	7.31e-05	0.000374	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—urinary bladder cancer	7.26e-05	0.000372	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—urinary bladder cancer	7.24e-05	0.00037	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—urinary bladder cancer	7.19e-05	0.000368	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—urinary bladder cancer	7.18e-05	0.000367	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—urinary bladder cancer	7.15e-05	0.000366	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—urinary bladder cancer	7.12e-05	0.000364	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.12e-05	0.000364	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.1e-05	0.000363	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—urinary bladder cancer	7.09e-05	0.000363	CcSEcCtD
Carvedilol—Infection—Doxorubicin—urinary bladder cancer	7.07e-05	0.000362	CcSEcCtD
Carvedilol—Pain—Methotrexate—urinary bladder cancer	7.03e-05	0.00036	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.01e-05	0.000359	CcSEcCtD
Carvedilol—Shock—Doxorubicin—urinary bladder cancer	7e-05	0.000358	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.97e-05	0.000357	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—urinary bladder cancer	6.96e-05	0.000356	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—urinary bladder cancer	6.95e-05	0.000356	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—urinary bladder cancer	6.91e-05	0.000354	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—urinary bladder cancer	6.91e-05	0.000354	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.88e-05	0.000352	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—urinary bladder cancer	6.86e-05	0.000351	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—urinary bladder cancer	6.84e-05	0.00035	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—urinary bladder cancer	6.78e-05	0.000347	CcSEcCtD
Carvedilol—Feeling abnormal—Methotrexate—urinary bladder cancer	6.77e-05	0.000347	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—urinary bladder cancer	6.77e-05	0.000347	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.72e-05	0.000344	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—urinary bladder cancer	6.69e-05	0.000342	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—urinary bladder cancer	6.65e-05	0.00034	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.64e-05	0.00034	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—urinary bladder cancer	6.63e-05	0.000339	CcSEcCtD
Carvedilol—Constipation—Epirubicin—urinary bladder cancer	6.58e-05	0.000337	CcSEcCtD
Carvedilol—Pain—Epirubicin—urinary bladder cancer	6.58e-05	0.000337	CcSEcCtD
Carvedilol—Urticaria—Methotrexate—urinary bladder cancer	6.53e-05	0.000334	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—urinary bladder cancer	6.5e-05	0.000333	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—urinary bladder cancer	6.5e-05	0.000333	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.48e-05	0.000332	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—urinary bladder cancer	6.44e-05	0.000329	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—urinary bladder cancer	6.39e-05	0.000327	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—urinary bladder cancer	6.35e-05	0.000325	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—urinary bladder cancer	6.34e-05	0.000324	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—urinary bladder cancer	6.33e-05	0.000324	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.29e-05	0.000322	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—urinary bladder cancer	6.26e-05	0.000321	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—urinary bladder cancer	6.19e-05	0.000317	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.14e-05	0.000315	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—urinary bladder cancer	6.14e-05	0.000314	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—urinary bladder cancer	6.11e-05	0.000313	CcSEcCtD
Carvedilol—Pain—Doxorubicin—urinary bladder cancer	6.09e-05	0.000312	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—urinary bladder cancer	6.09e-05	0.000312	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—urinary bladder cancer	6.08e-05	0.000311	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—urinary bladder cancer	6.08e-05	0.000311	CcSEcCtD
Carvedilol—Hypersensitivity—Methotrexate—urinary bladder cancer	6.06e-05	0.00031	CcSEcCtD
Carvedilol—Asthenia—Methotrexate—urinary bladder cancer	5.9e-05	0.000302	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.86e-05	0.0003	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.82e-05	0.000298	CcSEcCtD
Carvedilol—Pruritus—Methotrexate—urinary bladder cancer	5.82e-05	0.000298	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—urinary bladder cancer	5.67e-05	0.00029	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—urinary bladder cancer	5.65e-05	0.000289	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—urinary bladder cancer	5.63e-05	0.000288	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—urinary bladder cancer	5.63e-05	0.000288	CcSEcCtD
Carvedilol—Diarrhoea—Methotrexate—urinary bladder cancer	5.62e-05	0.000288	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—urinary bladder cancer	5.52e-05	0.000282	CcSEcCtD
Carvedilol—Pruritus—Epirubicin—urinary bladder cancer	5.44e-05	0.000279	CcSEcCtD
Carvedilol—Dizziness—Methotrexate—urinary bladder cancer	5.44e-05	0.000278	CcSEcCtD
Carvedilol—Diarrhoea—Epirubicin—urinary bladder cancer	5.26e-05	0.000269	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.24e-05	0.000268	CcSEcCtD
Carvedilol—Vomiting—Methotrexate—urinary bladder cancer	5.23e-05	0.000267	CcSEcCtD
Carvedilol—Rash—Methotrexate—urinary bladder cancer	5.18e-05	0.000265	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—urinary bladder cancer	5.18e-05	0.000265	CcSEcCtD
Carvedilol—Headache—Methotrexate—urinary bladder cancer	5.15e-05	0.000264	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—urinary bladder cancer	5.11e-05	0.000261	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—urinary bladder cancer	5.09e-05	0.00026	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—urinary bladder cancer	5.04e-05	0.000258	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—urinary bladder cancer	4.89e-05	0.00025	CcSEcCtD
Carvedilol—Nausea—Methotrexate—urinary bladder cancer	4.88e-05	0.00025	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—urinary bladder cancer	4.87e-05	0.000249	CcSEcCtD
Carvedilol—Rash—Epirubicin—urinary bladder cancer	4.85e-05	0.000248	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—urinary bladder cancer	4.85e-05	0.000248	CcSEcCtD
Carvedilol—Headache—Epirubicin—urinary bladder cancer	4.82e-05	0.000247	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—urinary bladder cancer	4.71e-05	0.000241	CcSEcCtD
Carvedilol—Nausea—Epirubicin—urinary bladder cancer	4.57e-05	0.000234	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—urinary bladder cancer	4.53e-05	0.000232	CcSEcCtD
Carvedilol—Rash—Doxorubicin—urinary bladder cancer	4.49e-05	0.00023	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—urinary bladder cancer	4.48e-05	0.000229	CcSEcCtD
Carvedilol—Headache—Doxorubicin—urinary bladder cancer	4.46e-05	0.000228	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—urinary bladder cancer	4.23e-05	0.000216	CcSEcCtD
Carvedilol—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	5.17e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	5.17e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	5.15e-06	2.73e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	5.15e-06	2.73e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	5.09e-06	2.7e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NQO1—urinary bladder cancer	5.04e-06	2.67e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PPARG—urinary bladder cancer	5.01e-06	2.66e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.99e-06	2.64e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	4.97e-06	2.63e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.96e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CREBBP—urinary bladder cancer	4.96e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—urinary bladder cancer	4.95e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	4.94e-06	2.62e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—urinary bladder cancer	4.94e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	4.93e-06	2.61e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB2—urinary bladder cancer	4.92e-06	2.61e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	4.92e-06	2.61e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IGF1—urinary bladder cancer	4.9e-06	2.59e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.89e-06	2.59e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.89e-06	2.59e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	4.88e-06	2.59e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—urinary bladder cancer	4.87e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	4.86e-06	2.58e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—urinary bladder cancer	4.86e-06	2.57e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—urinary bladder cancer	4.85e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	4.85e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.84e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.84e-06	2.56e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.82e-06	2.56e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.82e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	4.82e-06	2.55e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	4.82e-06	2.55e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	4.8e-06	2.54e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	4.79e-06	2.54e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.76e-06	2.52e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	4.74e-06	2.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	4.73e-06	2.51e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.68e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCL8—urinary bladder cancer	4.67e-06	2.47e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—urinary bladder cancer	4.64e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.63e-06	2.45e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.61e-06	2.44e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PPARG—urinary bladder cancer	4.6e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—urinary bladder cancer	4.6e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	4.59e-06	2.43e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.57e-06	2.42e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.56e-06	2.42e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.56e-06	2.42e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.55e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	4.53e-06	2.4e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.52e-06	2.39e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.52e-06	2.39e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	4.49e-06	2.38e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	4.48e-06	2.38e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2—urinary bladder cancer	4.46e-06	2.36e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	4.44e-06	2.36e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	4.42e-06	2.34e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	4.41e-06	2.34e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—urinary bladder cancer	4.4e-06	2.33e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—urinary bladder cancer	4.39e-06	2.33e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	4.39e-06	2.33e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.37e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCND1—urinary bladder cancer	4.35e-06	2.3e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PPARG—urinary bladder cancer	4.34e-06	2.3e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	4.33e-06	2.3e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GPX1—urinary bladder cancer	4.33e-06	2.29e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.29e-06	2.27e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	4.28e-06	2.27e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.27e-06	2.27e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.26e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	4.26e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	4.25e-06	2.25e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.25e-06	2.25e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTEN—urinary bladder cancer	4.23e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	4.23e-06	2.24e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTEN—urinary bladder cancer	4.23e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—urinary bladder cancer	4.22e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	4.22e-06	2.23e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CDKN1A—urinary bladder cancer	4.21e-06	2.23e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—urinary bladder cancer	4.21e-06	2.23e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	4.2e-06	2.23e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTEN—urinary bladder cancer	4.2e-06	2.22e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—urinary bladder cancer	4.2e-06	2.22e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	4.19e-06	2.22e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	4.17e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	4.16e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	4.15e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	4.13e-06	2.19e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	4.09e-06	2.17e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.07e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	4.07e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—EP300—urinary bladder cancer	4.04e-06	2.14e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—EP300—urinary bladder cancer	4.03e-06	2.14e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	4.03e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	4.03e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	4.03e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	4.02e-06	2.13e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	4e-06	2.12e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.99e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	3.98e-06	2.11e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	3.98e-06	2.11e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	3.96e-06	2.1e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	3.96e-06	2.1e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	3.94e-06	2.09e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	3.94e-06	2.09e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	3.93e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	3.92e-06	2.08e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	3.91e-06	2.07e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.91e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	3.89e-06	2.06e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.89e-06	2.06e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	3.88e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	3.87e-06	2.05e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.86e-06	2.05e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.86e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	3.85e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	3.85e-06	2.04e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	3.83e-06	2.03e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	3.83e-06	2.03e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	3.81e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.8e-06	2.01e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	3.79e-06	2.01e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	3.76e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	3.76e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	3.75e-06	1.99e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	3.74e-06	1.98e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	3.74e-06	1.98e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	3.7e-06	1.96e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.7e-06	1.96e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	3.67e-06	1.94e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	3.65e-06	1.93e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	3.64e-06	1.93e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.63e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	3.63e-06	1.92e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	3.62e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	3.61e-06	1.92e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	3.61e-06	1.91e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	3.57e-06	1.89e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	3.56e-06	1.89e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	3.55e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	3.55e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	3.54e-06	1.88e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	3.51e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	3.5e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.49e-06	1.85e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	3.49e-06	1.85e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	3.48e-06	1.85e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	3.47e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.47e-06	1.84e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	3.44e-06	1.82e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—urinary bladder cancer	3.44e-06	1.82e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	3.42e-06	1.81e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	3.41e-06	1.81e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	3.41e-06	1.81e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	3.41e-06	1.81e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	3.38e-06	1.79e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	3.37e-06	1.79e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.33e-06	1.76e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	3.32e-06	1.76e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	3.29e-06	1.74e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	3.28e-06	1.74e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—EP300—urinary bladder cancer	3.28e-06	1.74e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.27e-06	1.73e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.24e-06	1.72e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.24e-06	1.72e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	3.23e-06	1.71e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	3.22e-06	1.71e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	3.21e-06	1.7e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	3.2e-06	1.69e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	3.18e-06	1.68e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	3.18e-06	1.68e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—urinary bladder cancer	3.16e-06	1.67e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	3.15e-06	1.67e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.14e-06	1.66e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	3.11e-06	1.65e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.11e-06	1.65e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	3.11e-06	1.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	3.11e-06	1.65e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.1e-06	1.64e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	3.1e-06	1.64e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	3.08e-06	1.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	3.06e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	3.04e-06	1.61e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.01e-06	1.6e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—EP300—urinary bladder cancer	3.01e-06	1.6e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.98e-06	1.58e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.98e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	2.98e-06	1.58e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—urinary bladder cancer	2.98e-06	1.58e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	2.95e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	2.94e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	2.94e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	2.91e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	2.9e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	2.89e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.88e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	2.88e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	2.88e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	2.87e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	2.87e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	2.87e-06	1.52e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.85e-06	1.51e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—EP300—urinary bladder cancer	2.84e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	2.83e-06	1.5e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.8e-06	1.48e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.77e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	2.74e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	2.74e-06	1.45e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.73e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	2.72e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	2.68e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	2.67e-06	1.41e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.66e-06	1.41e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.63e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	2.61e-06	1.38e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	2.59e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	2.57e-06	1.36e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.57e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	2.55e-06	1.35e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.55e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	2.52e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	2.5e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	2.47e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	2.44e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	2.42e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	2.39e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.38e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	2.38e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	2.38e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	2.34e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	2.31e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	2.27e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—EP300—urinary bladder cancer	2.27e-06	1.2e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.24e-06	1.19e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.22e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	2.21e-06	1.17e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	2.18e-06	1.15e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.14e-06	1.13e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.14e-06	1.13e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.12e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	2.11e-06	1.12e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.05e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	2.02e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	1.96e-06	1.04e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.9e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.88e-06	9.95e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.81e-06	9.59e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.68e-06	8.9e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.47e-06	7.76e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.4e-06	7.4e-06	CbGpPWpGaD
